BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,618
Mkt Cap
$1.96B
Volume
14.88M
52W High
$11.31
52W Low
$6.00
PE Ratio
-167.02
BCRX Fundamentals
Price
$8.75
Prev Close
$7.90
Open
$7.95
50D MA
$7.13
Beta
0.91
Avg. Volume
4.96M
EPS (Annual)
-$0.43
P/B
-4.29
Rev/Employee
$777,089.66
$2,074.71
Loading...
Loading...
News
all
press releases
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 10.7% Higher on Better-Than-Expected Earnings...
MarketBeat·12h ago
News Placeholder
More News
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock...
MarketBeat·22h ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating...
MarketBeat·1d ago
News Placeholder
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +1,623.08% and +172.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
BioCryst Pharmaceuticals Q4 Earnings Call Highlights
BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined its full-year 2025 performance and priorities for 2026 during its fourth-quarter conference call, highlighting strong growth for its hereditary...
MarketBeat·1d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Strong Earnings...
MarketBeat·2d ago
News Placeholder
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
Public Sector Pension Investment Board Takes $2.01 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX
Public Sector Pension Investment Board purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the third quarter, according to its most recent filing with the...
MarketBeat·5d ago
News Placeholder
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·9d ago
News Placeholder
BioCryst Pharmaceuticals (BCRX) to Release Earnings on Thursday
BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·9d ago
<
1
2
...
>

Latest BCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.